Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/07/2010WO2010111948A1 Arylmethylamine compounds, preparation methods and pharmaceutical uses thereof
10/07/2010WO2010111935A1 New salvianolic acid compound l, preparation method and use thereof
10/07/2010WO2010111934A1 Lithium derivatives of pyrroloquinoline quinone and preparation method thereof
10/07/2010WO2010111905A1 Pharmaceutical composition for treatment of 2 type dabetes
10/07/2010WO2010111891A1 Modified oligo-nucleic acid molecule, preparation method and uses thereof
10/07/2010WO2010111807A1 A polysaccharide liposome, the preparation method and use of it
10/07/2010WO2010111792A1 Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
10/07/2010WO2010111777A1 Novel sodium channel blocking compounds tetrodotoxin galactopyranosides
10/07/2010WO2010111759A1 Stabiliser-free pharmaceutical compositions of tetrahydrolipstatin
10/07/2010WO2010111745A1 Compositions and methods for increasing vitamin c uptake into cells and methods for retarding skin ageing, lightening skin and modulating hair colour
10/07/2010WO2010094009A3 Methods and compositions for the treatment of ras associated disorders
10/07/2010WO2010093843A3 Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
10/07/2010WO2010093788A3 Multiplex dicer substrate rna interference molecules having joining sequences
10/07/2010WO2010091067A3 Derivatives of [1, 3] oxazin- 2-one useful for the treatment of metabolic diseases such as lipid disorders
10/07/2010WO2010084111A3 Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
10/07/2010WO2010082220A3 Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
10/07/2010WO2010081862A3 Methods and preparations for protecting critically ill patients with a polyamine (e.g. spermine, spermidine)
10/07/2010WO2010080213A3 Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
10/07/2010WO2010079914A3 A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases
10/07/2010WO2010079910A3 Eyesight-protecting composition containing functional components having preventive and therapeutic efficacy in diabetes or diabetes complications
10/07/2010WO2010075861A3 Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
10/07/2010WO2010071313A3 Granules containing lacidipine, and pharmaceutical compositions comprising same
10/07/2010WO2010069795A3 Capecitabine rapidly disintegrating tablets
10/07/2010WO2010065824A3 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
10/07/2010WO2010065709A3 Hydroxamic acid derivatives, preparation and therapeutic uses thereof
10/07/2010WO2010065660A3 Biodegradable polydisulfide amines for gene delivery
10/07/2010WO2010063470A9 Methods for preventing or reducing colon carcinogenesis
10/07/2010WO2010062506A3 Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
10/07/2010WO2010062136A3 Composition for mitochondrial activation
10/07/2010WO2010059662A9 Constitutive androstane receptor (car) as a therapeutic target for obesity and type two diabetes
10/07/2010WO2010058104A3 Pharmaceutical compositions containing inulin as granulation carrier
10/07/2010WO2010055072A3 Treating cancer by modulating a mnk
10/07/2010WO2010052430A3 Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine
10/07/2010WO2010044637A9 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
10/07/2010WO2010043866A3 Histone lysine demethylase inhibitors
10/07/2010WO2010039825A3 Imidazo [1, 2-a] pyridine compounds as receptor tyrosine kinase inhibitors
10/07/2010WO2010019435A3 Solid states of atorvastatin potassium
10/07/2010WO2009149150A3 Composition comprising liposome-entrapped doxorubicin and methods of administration
10/07/2010WO2009136563A8 Moisturizing agent
10/07/2010WO2009122404A3 Device for in situ production and topical administration of allicin
10/07/2010WO2009109388A8 Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
10/07/2010WO2009106986A3 Nonstructural protein ns1 as a novel therapeutic target against flaviviruses: use of inhibiting molecules interfering with ns1 maturation or biological activity
10/07/2010WO2009105969A8 Epothilone analogues, their pharmaceutical compositions, their use and their preparations
10/07/2010WO2008059501A8 Use of lipid conjugates in the treatment of diseases or disorders of the eye
10/07/2010US20100257616 DNA regulatory element for the expression of transgenes in neurons of a subject and uses thereof
10/07/2010US20100256746 Biodegradable polymers
10/07/2010US20100256698 Isoquinolinone Potassium Channel Inhibitors
10/07/2010US20100256576 Disinfectant Compositions, Methods and Systems
10/07/2010US20100256401 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
10/07/2010US20100256367 Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives
10/07/2010US20100256361 Thiazole derivatives
10/07/2010US20100256359 Hetero isonipecotic modulators of vanilloid vr1 receptor
10/07/2010US20100256341 Treatment of inflammation using alpha 7 receptor-binding cholinergic agonists
10/07/2010US20100256243 Dosing Regimen for the Treatment of Alzheimer's Disease With Sulfonyl Fluorides
10/07/2010US20100256241 Method for treating atypical facial pain
10/07/2010US20100256240 Prostacyclin derivatives
10/07/2010US20100256239 Anthracenedione compounds
10/07/2010US20100256238 Emulsion-type external preparation, and method for production thereof
10/07/2010US20100256237 Potentiating the effect of compound comprising nitric oxide
10/07/2010US20100256236 Methods for decreasing cartilage damage in dogs
10/07/2010US20100256235 Dietary formulations and methods for treatment of inflammation and other disorders
10/07/2010US20100256234 Method for Stimulating the Proliferation of Differentiated Cells Belonging to the Chondrogenic Lineage
10/07/2010US20100256233 Systems, methods and compositions for reduction of injury from radiation exposure
10/07/2010US20100256232 Cancer Therapy
10/07/2010US20100256231 Novel derivatives of 3,3-diphenylpropylamines
10/07/2010US20100256230 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
10/07/2010US20100256229 Compositions of cholinesterase inhibitors
10/07/2010US20100256227 Use of azaphilone compounds for the modulation of the activity of a nuclear hormone receptor
10/07/2010US20100256226 Eg-vegf nucleic acids and polypeptides and methods of use
10/07/2010US20100256225 Constructs containing multiple expression cassettes for cancer therapy
10/07/2010US20100256224 Novel angiogenesis inhibitor
10/07/2010US20100256223 Oligonucleotides for modulating target rna activity
10/07/2010US20100256222 Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas
10/07/2010US20100256221 Methods and compositions for treating neuropathic and neurodegenerative conditions
10/07/2010US20100256220 PAS Kinase Regulates Energy Homeostasis
10/07/2010US20100256219 Small interfering DNA (siDNA) oligonucleotides as an antiviral agent against Herpes virus infections
10/07/2010US20100256218 RNAi MODULATION OF MLL-AF4 AND USES THEREOF
10/07/2010US20100256217 Antiviral inhibition of casein kinase ii
10/07/2010US20100256216 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
10/07/2010US20100256215 Menthol-Melatonin Dissolving Film
10/07/2010US20100256214 Eph receptor ligands and methods of use
10/07/2010US20100256213 Tosylate Salt Of Trans-N-Isobutyl-3-Fluoro-3- [3-Fluoro-4-(Pyrrolidin-1-YL-Methyl)-Phenyl] Cyclobut Anecarboxamide
10/07/2010US20100256212 Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
10/07/2010US20100256211 Inhibition of Chronic Tissue Transplant Rejection
10/07/2010US20100256210 Methods and compositions for delivering 5-ht3 antagonists across the oral mucosa
10/07/2010US20100256209 Compositions comprising ether compounds and pharmaceutical uses therefor
10/07/2010US20100256208 Novel process
10/07/2010US20100256207 Amorphous olmesartan medoxomil
10/07/2010US20100256206 Crystalline form b of olmesartan medoxomil
10/07/2010US20100256203 Benzimidazoles and pharmaceutical compositions thereof
10/07/2010US20100256202 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof
10/07/2010US20100256201 Cell differentiation inducer
10/07/2010US20100256200 Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
10/07/2010US20100256199 Crystalline form of an Antimalarial Compound
10/07/2010US20100256198 Method for decreasing symptoms of alcohol consumption
10/07/2010US20100256197 Nicotine Dissolving Film With Or Without Menthol
10/07/2010US20100256196 Biomarkers for Atherosclerosis
10/07/2010US20100256194 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
10/07/2010US20100256193 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
10/07/2010US20100256192 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same
1 ... 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 ... 7860